West Pharmaceutical Services, Inc.
WST · New York Stock Exchange · USD
413,09USD
+13,28 (+3,32 %)Stand 9. Nov., 21:00
Vorbörslich413,090,00 (0,00 %)7:59 ET
Kennzahlen
- Eröffnung
- 403,07
- Vortag
- 399,81
- Tagesspanne
- 398,14 – 415,40
- 52 Wochen
- 223,83 – 438,27
- Volumen
- 555.247
- Ø Volumen
- 658.835
- Börsenwert
- 28,78 Mrd. $
- KGV
- 46,1
- Gewinn je Aktie (TTM)
- 8,91
- Dividendenrendite
- 0,2 %
- Beta
- 1,1
- Nächste Zahlen
- 11. Feb. 2027
Finanzen
| USD | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 3,07 Mrd. | 2,89 Mrd. | 2,95 Mrd. | 2,89 Mrd. | 2,83 Mrd. |
| Herstellungskosten | 1,97 Mrd. | 1,89 Mrd. | 1,82 Mrd. | 1,75 Mrd. | 1,66 Mrd. |
| Bruttogewinn | 1,1 Mrd. | 1 Mrd. | 1,13 Mrd. | 1,14 Mrd. | 1,17 Mrd. |
| Forschung und Entwicklung | 74,3 Mio. | 69,1 Mio. | 68,4 Mio. | 58,5 Mio. | 52,8 Mio. |
| Vertrieb und Verwaltung | 393,1 Mio. | 338,5 Mio. | 353,4 Mio. | 316,9 Mio. | 361,9 Mio. |
| Operatives Ergebnis | 617,4 Mio. | 594,6 Mio. | 710,9 Mio. | 763,5 Mio. | 758,7 Mio. |
| EBITDA | 770,6 Mio. | 743,8 Mio. | 844,1 Mio. | 808,1 Mio. | 879,7 Mio. |
| Nettogewinn | 493,7 Mio. | 492,7 Mio. | 593,4 Mio. | 585,9 Mio. | 661,8 Mio. |
| Gewinn je Aktie (verwässert) | 6,80 | 6,69 | 7,88 | 7,73 | 8,67 |
Umsatz nach Segment
Produkte · FY 2025
- Proprietary Products2,49 Mrd. $81,07 %+6,75 %
- Contract Manufactured Products582 Mio. $18,93 %+4,17 %
Anteil · ggü. Vorjahr (FY 2024)
Regionen · FY 2025
- UNITED STATES1,33 Mrd. $43,25 %+8,03 %
- Other Europe Countries451 Mio. $14,67 %+16,99 %
- GERMANY380,3 Mio. $12,37 %+2,09 %
- Other Countries353,3 Mio. $11,49 %+4,22 %
- IRELAND333,3 Mio. $10,84 %+3,13 %
- FRANCE226,6 Mio. $7,37 %−6,44 %
Anteil · ggü. Vorjahr (FY 2024)
Bewertung
Letzte 12 Monate
- KGV
- 46,1
- Kurs-Umsatz-Verhältnis
- 8,5
- Kurs-Buchwert-Verhältnis
- 9,8
- PEG
- 1,4
- Bruttomarge
- 37,6 %
- Operative Marge
- 23,0 %
- Nettomarge
- 18,8 %
- Verschuldungsgrad
- 0,1
- EV/EBITDA
- 29,6
- Eigenkapitalrendite
- 21,1 %
- Kapitalrendite (ROIC)
- 17,9 %
- Free-Cashflow-Rendite
- 1,6 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 35,9 % | 34,6 % | 38,4 % | 39,5 % | 41,5 % |
| Operative Marge | 20,1 % | 20,6 % | 24,1 % | 26,5 % | 26,8 % |
| Nettomarge | 16,1 % | 17,0 % | 20,1 % | 20,3 % | 23,4 % |
| KGV | 40,3 | 48,5 | 44,1 | 29,9 | 52,7 |
| Kurs-Umsatz-Verhältnis | 6,5 | 8,3 | 8,9 | 6,1 | 12,3 |
| Kurs-Buchwert-Verhältnis | 6,3 | 8,9 | 9,1 | 6,5 | 14,9 |
| Verschuldungsgrad | 0,1 | 0,1 | 0,1 | 0,1 | 0,1 |
| Liquidität 3. Grades | 3,0 | 2,8 | 2,9 | 3,7 | 2,9 |
| Dividendenrendite | 0,3 % | 0,2 % | 0,2 % | 0,3 % | 0,1 % |
| Unternehmenswert | 19,52 Mrd. | 23,73 Mrd. | 25,62 Mrd. | 16,93 Mrd. | 34,46 Mrd. |
| EV/EBITDA | 25,3 | 31,9 | 30,3 | 21,0 | 39,2 |
| Eigenkapitalrendite | 15,5 % | 18,4 % | 20,6 % | 21,8 % | 28,3 % |
| Kapitalrendite (ROIC) | 13,6 % | 15,7 % | 17,8 % | 20,5 % | 23,5 % |
| Free-Cashflow-Rendite | 2,4 % | 1,2 % | 1,6 % | 2,5 % | 0,9 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | +6,3 % | −2,0 % | +2,3 % | +1,9 % | +31,9 % |
| Bruttogewinn | +10,1 % | −11,5 % | −0,5 % | −2,9 % | +52,8 % |
| Operatives Ergebnis | +3,8 % | −16,4 % | −6,9 % | +0,6 % | +81,1 % |
| Nettogewinn | +0,2 % | −17,0 % | +1,3 % | −11,5 % | +91,2 % |
| Gewinn je Aktie | +1,6 % | −15,1 % | +1,9 % | −10,8 % | +89,7 % |
| Freier Cashflow | +69,6 % | −33,3 % | −5,7 % | +32,9 % | +10,9 % |
| Dividende je Aktie | +4,6 % | +5,5 % | +5,5 % | +5,9 % | +5,5 % |
Analysten
Einstufungen · Buy
- 0Stark kaufen
- 14Kaufen
- 2Halten
- 1Verkaufen
- 0Stark verkaufen
Kursziel
427,43
Durchschnitt · +3,47 %
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 3,42 Mrd. | 3,62 Mrd. | 3,91 Mrd. |
| Umsatz (Tief – Hoch) | 3,38 Mrd. – 3,44 Mrd. | 3,52 Mrd. – 3,71 Mrd. | 3,78 Mrd. – 4,03 Mrd. |
| Gewinn je Aktie (Ø) | 9,49 | 10,36 | 11,88 |
| Gewinn je Aktie (Tief – Hoch) | 9,00 – 9,63 | 9,48 – 10,79 | 11,03 – 12,72 |
| Analysten | 9 | 10 | 7 |
Letzte Änderungen
- Citigroup30. Okt. 2026Buy
- TD Cowen30. Okt. 2026Buy
- Barclays30. Okt. 2026Overweight
- Evercore ISI Group30. Okt. 2026Outperform
- TD Cowen13. Okt. 2026Buy
- Barclays7. Okt. 2026Overweight
- Morgan Stanley22. Sept. 2026Equal Weight → Overweight
- UBS9. Sept. 2026Buy
Quartalszahlen
Nächste Zahlen: 11. Feb. 2027| Okt. 2026 | Juli 2026 | Apr. 2026 | Feb. 2026 | Okt. 2025 | Juli 2025 | Apr. 2025 | Feb. 2025 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | 2,20 | 2,08 | 1,68 | 1,83 | 1,68 | 1,51 | 1,22 | 1,71 |
| Gewinn je Aktie · Tatsächlich | 2,66 | 2,37 | 2,13 | 2,04 | 1,96 | 1,84 | 1,45 | 1,82 |
| Abweichung | +20,91 % | +13,94 % | +26,79 % | +11,48 % | +16,67 % | +21,85 % | +18,85 % | +6,43 % |
| Umsatz · Tatsächlich | 874,5 Mio. | 872,3 Mio. | 844,9 Mio. | 805 Mio. | 804,3 Mio. | 766,2 Mio. | 698 Mio. | 748,8 Mio. |
Dividenden und Splits
| Ex-Tag | Zahltag | Betrag |
|---|---|---|
| 10. Nov. 2026 | 18. Nov. 2026 | 0,26 |
| 29. Juli 2026 | 5. Aug. 2026 | 0,22 |
| 29. Apr. 2026 | 6. Mai 2026 | 0,22 |
| 28. Jan. 2026 | 4. Feb. 2026 | 0,22 |
| 12. Nov. 2025 | 19. Nov. 2025 | 0,22 |
| 30. Juli 2025 | 6. Aug. 2025 | 0,21 |
| 30. Apr. 2025 | 7. Mai 2025 | 0,21 |
| 7. Feb. 2025 | 11. Feb. 2025 | 0,21 |
| 13. Nov. 2024 | 20. Nov. 2024 | 0,21 |
| 31. Juli 2024 | 7. Aug. 2024 | 0,20 |
| 23. Apr. 2024 | 1. Mai 2024 | 0,20 |
| 30. Jan. 2024 | 7. Feb. 2024 | 0,20 |
Aktiensplits
- 27. Sept. 20132:1
- 30. Sept. 20042:1
- 2. Juni 19872:1
- 6. Mai 19822:1
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 98,71 %
- Investoren mit 13F-Meldung
- 860
Größte Investoren
- BLACKROCK, INC.9,40 %6,65 Mio.
- VANGUARD CAPITAL MANAGEMENT LLC6,52 %4,61 Mio.
- VANGUARD PORTFOLIO MANAGEMENT LLC5,67 %4,02 Mio.
- FMR LLC5,05 %3,57 Mio.
- STATE STREET CORP4,65 %3,35 Mio.
- ARTISAN PARTNERS LIMITED PARTNERSHIP3,41 %2,41 Mio.
- BANK OF NEW YORK MELLON CORP2,89 %2,04 Mio.
- GENERATION INVESTMENT MANAGEMENT LLP2,86 %2,03 Mio.
Insider-Geschäfte
- HAUGEN JANET BRUTSCHEA30. Sept. 2026 · directorKauf44 Aktien
- Favorite Annette F15. Sept. 2026 · officer: Sr. VP & Chief HR OfficerKauf2524 Aktien · 89,64
- Favorite Annette F15. Sept. 2026 · officer: Sr. VP & Chief HR OfficerVerkauf2524 Aktien · 365,00
- Favorite Annette F15. Sept. 2026 · officer: Sr. VP & Chief HR OfficerVerkauf2524 Aktien · 89,64
- Favorite Annette F14. Sept. 2026 · officer: Sr. VP & Chief HR OfficerKauf2500 Aktien · 89,64
- Favorite Annette F14. Sept. 2026 · officer: Sr. VP & Chief HR OfficerVerkauf2500 Aktien · 355,00
- Favorite Annette F14. Sept. 2026 · officer: Sr. VP & Chief HR OfficerVerkauf2500 Aktien · 89,64
- Favorite Annette F11. Sept. 2026 · officer: Sr. VP & Chief HR OfficerVerkauf2500 Aktien · 345,00
Vergleichbare Unternehmen
Über das Unternehmen
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
Führung
- Robert W. McMahonSenior Vice President & Chief Financial Officer
- Eric GreenNon-Independent Chair of the Board, President & Chief Executive Officer
- Devesh MathurSenior Vice President & Chief Technology Officer
- Shane CampbellSVP & Chief Proprietary Segment Officer
- Annette F. FavoriteChief Human Resources Officer & Senior Vice President
- Chad R. WintersVice President of Finance & Chief Accounting Officer
- CEO
- Michel Lagarde
- Mitarbeitende
- 10.800
- Hauptsitz
- Exton, PA, US
- Sektor
- Healthcare
- Branche
- Medical - Instruments & Supplies
- Börsengang
- 17. März 1980
- Website
- westpharma.com
Nachrichten
- Defense World · 9. Nov., 4:05Candriam S.C.A. Purchases 3,140 Shares of West Pharmaceutical Services, Inc. $WST
- Zacks Investment Research · 5. Nov., 13:01West Pharmaceutical Services (WST) is a Great Momentum Stock: Should You Buy?
- PRNewsWire · 4. Nov., 6:00West to Participate in Upcoming Investor Conference
- Defense World · 4. Nov., 4:01West Pharmaceutical Services, Inc. $WST Stock Position Raised by Bank Julius Baer & Co. Ltd Zurich
- MarketBeat · 31. Okt., 2:14What West Pharmaceutical Services (WST) Said on Its Q3 Earnings Call
- Seeking Alpha · 29. Okt., 13:39West Pharmaceutical Services, Inc. (WST) Q3 2026 Earnings Call Transcript
- Zacks Investment Research · 29. Okt., 13:06West Pharma Q3 Earnings Rise on HVP Strength, 2026 Outlook Raised
- Zacks Investment Research · 29. Okt., 10:31Compared to Estimates, West Pharmaceutical (WST) Q3 Earnings: A Look at Key Metrics
- Zacks Investment Research · 29. Okt., 8:11West Pharmaceutical Services (WST) Q3 Earnings and Revenues Top Estimates
- PRNewsWire · 29. Okt., 6:00West Reports Third-Quarter 2026 Results
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.